The anticholinergic agent ipratropium bromide is front-line therapy for patients with nonasthmatic COPD (1). In most of these patients, ipratropium used alone is more effective as a bronchodilator than is an inhaled β-agonist used alone. (Combination therapy, however, is often more effective than either agent used alone.) Ipratropium bromide has a relatively short duration of action, requiring inhalation every 6 to 8 hours. In addition, ipratropium nonselectively inhibits all 3 of the known muscarinic receptors in the human airway (M 1 , M 2 , and M 3 ). This is of theoretical concern because the M 2 receptor normally acts as a feedback inhibitory receptor; blockade of the M 2 receptor results in increased acetylcholine release in the airway and could attenuate or reverse the bronchodilation achieved by blockade of the M 1 and M 3 receptors (2). The clinical relevance of this issue is uncertain.
C o m m e n t a r y
The anticholinergic agent ipratropium bromide is front-line therapy for patients with nonasthmatic COPD (1) . In most of these patients, ipratropium used alone is more effective as a bronchodilator than is an inhaled β-agonist used alone. (Combination therapy, however, is often more effective than either agent used alone.) Ipratropium bromide has a relatively short duration of action, requiring inhalation every 6 to 8 hours. In addition, ipratropium nonselectively inhibits all 3 of the known muscarinic receptors in the human airway (M 1 , M 2 , and M 3 ). This is of theoretical concern because the M 2 receptor normally acts as a feedback inhibitory receptor; blockade of the M 2 receptor results in increased acetylcholine release in the airway and could attenuate or reverse the bronchodilation achieved by blockade of the M 1 and M 3 receptors (2). The clinical relevance of this issue is uncertain.
Tiotropium is a potent and long-lasting muscarinic antagonist that has "kinetic selectivity" for M 1 and M 3 receptors over M 2 receptors (2). A single dose of inhaled tiotropium produces bronchodilation for 24 hours in patients with COPD (3) and attenuates methacholineinduced bronchoconstriction for 48 hours in patients with asthma (4). Once-daily dosing for 4 weeks in stable patients with COPD provides sustained bronchodilation with an excellent safety profile (5). 
S e t t i n g
14 centers in the Netherlands.
P a t i e n t s
288 patients ≥ 40 years of age (mean age 64 y, 83% men) who were current or past smokers with a diagnosis of COPD and stable airways obstruction, an FEV 1 < 65% of the predicted normal rate, and a ratio of FEV 1 to forced vital capacity (FVC) of < 70%. Exclusion criteria included a history of asthma, allergic rhinitis, or atopy; a recent history of myocardial infarction, heart failure, or cardiac arrhythmia requiring drug treatment; upper respiratory tract infection in the past 6 weeks; and hypersensitivity to anticholinergic drugs. 90% completed all tests.
I n t e r v e n t i o n 191 patients were assigned to tiotropium, 18 µg once daily, delivered by a dry-powder inhaler system; and 97 were assigned to ipratropium, 40 µg 4 times daily, delivered by a metered-dose inhaler. Each group also received placebo doses of the other treatment.
M a i n o u t c o m e m e a s u r e s
Lung function, peak expiratory flow (PEF), use of concomitant salbutamol, and adverse effects.
M a i n r e s u l t s
Trough, peak, and mean FEV 1 response and trough and mean FVC response showed greater improvement with tiotropium than with ipratropium (Table) . Morning and evening PEF was consistently better with tiotropium (P < 0.05). Use of concomitant salbutamol was lower in the tiotropium group (P < 0.05). The groups did not differ for adverse effects.
C o n c l u s i o n s
In patients with chronic obstructive pulmonary disease, tiotropium improved lung function more than did ipratropium. The safety profiles of the 2 drugs were similar. 
